In a regulatory filing, Ventyx Biosciences director Somu Subramaniam disclosed the sale of 49,152 common shares of the company on October 9 at a price of $30.0264 per share.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VTYX:
- Ventyx Biosciences price target lowered to $47 from $65 at Evercore ISI
- Ventyx Biosciences price target lowered to $56 from $57 at Oppenheimer
- Ventyx Biosciences Phase 2 trial of VTX002 for UC meets primary endpoint
- Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002 in Patients with Moderate-to-Severely Active Ulcerative Colitis
- Cantor Fitzgerald biotech analysts to hold an analyst/industry conference call